The aim of the PRO B study is to examine whether the positive effects of intensified patient-reported outcomes monitoring can be transferred to the usual care of patients with metastatic breast carcinoma in Germany. PRO B is a prospective, multicentre, randomised two-arm intervention study. Depending on randomisation, patients are asked about their health status weekly (intervention arm) or every three months (control arm) via smartphone app or email. A deterioration of the values is indicated to the treating centre by an automatic alarm. The centre then decides whether to contact the patient to specify the deterioration in values and initiate measures if necessary. PRO B uses the existing certification structures of the participating breast cancer centres to link clinical data with the collected PROs.
Charité – Universitätsmedizin Berlin
German Cancer Society (DKG)
Innovation Committee of The Federal Joint Committee (G-BA)
October 2020 – September 2024